TNFi治疗类风湿关节炎患者狼疮样及血管炎样事件风险:BSRBR-RA结果
倾向评分校正后,两组LLE和VLE风险无显著差异。
要点
- 校正基线特征后,TNFi与nbDMARD的LLE和VLE风险无显著差异。
- 两类事件风险在TNFi治疗第一年最高,英夫利西单抗总体风险最高。
核心结论
- 在因TNFi适应症选择的RA患者中,加用TNFi不改变LLE或VLE风险。
- 两种事件的绝对风险均较低。
研究设计与样本
- 英国风湿病学会生物制剂注册-RA(BSRBR-RA)前瞻性队列研究,2001-2015年招募。
- nbDMARD对照组为生物制剂初治患者n=3673。
- 采用倾向评分校正的Cox比例风险模型比较事件风险。
主要发现
- 校正后LLE风险无差异(adjHR 1.86;95%CI 0.52-6.58)。
- 校正后VLE风险无差异(adjHR 1.27;95%CI 0.40-4.04)。
- 英夫利西单抗总体风险最高,依那西普次之,但校正后95%CI重叠。
关键数值与推荐
- LLE校正后风险比:adjHR 1.86(95%CI 0.52-6.58)。
- VLE校正后风险比:adjHR 1.27(95%CI 0.40-4.04)。
临床怎么用
- RA患者使用TNFi时LLE和VLE绝对风险低,不应因此过度担忧。
- 治疗第一年需关注LLE和VLE事件,尤其使用英夫利西单抗者。
- 校正混杂因素后TNFi不增加LLE/VLE风险,支持在适应症患者中安全使用。
局限性
- 观察性队列研究,可能存在未测量混杂。
- 事件数量较少导致风险比置信区间宽。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To compare the risk of lupus-like events (LLEs) and vasculitis-like events (VLEs) in tumour necrosis factor-α inhibitor (TNFi)-treated patients with rheumatoid arthritis (RA) to those receiving non-biological disease-modifying antirheumatic drugs (nbDMARDs). METHODS: Patients were recruited to the British Society for Rheumatology Biologics Register-RA, a national prospective cohort study. Two cohorts recruited between 2001 and 2015: (1) patients starting first TNFi (adalimumab, etanercept, infliximab and certolizumab) (n=12 937) and (2) biological-naïve comparison cohort receiving nbDMARDs (n=3673). The risk of an event was compared between the two cohorts using Cox proportional-hazard models, adjusted using propensity scores. Rates of LLE/VLE were compared between TNFi and nbDMARD patients. RESULTS: The crude incidence rates for LLEs were: TNFi 10/10 000 patient-years (pyrs) (95% CI 8 to 13) and nbDMARD 2/10 000 pyrs (95% CI 1 to 6); for VLEs: TNFi 15/10 000 pyrs (95% CI 12 to 19) and nbDMARD 7/10 000 pyrs (95% CI 4 to 12). The risk of both events was highest in the first year of TNFi treatment. After adjusting for differences in baseline characteristics, there was no difference in risk of LLEs (adjHR 1.86; 95% CI 0.52 to 6.58) or VLEs (adjHR 1.27; 95% CI 0.40 to 4.04) for TNFi compared to nbDMARD-treated patients. Infliximab conferred the highest overall risk, followed by etanercept, although 95% CIs overlapped following adjustment. CONCLUSIONS: In one of the largest biological registers, the absolute risk of both events is low. The addition of TNFi to nbDMARD does not alter the risk of either event in patients with RA selected for TNFi. This is the first study to assess the risk of these outcomes in a prospective, observational cohort.
引用
- Jani M, Dixon WG, Kersley-Fleet L, et al. Drug-specific risk and characteristics of lupus and vasculitis-like events in patients with rheumatoid arthritis treated with TNFi: results from BSRBR-RA. RMD Open. 2017. PMID: 28123776. doi:10.1136/rmdopen-2016-000314
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。